Compare Twist Bioscience Corp (TWST) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Veritone Inc — how do they compare? Twist Bioscience Corp trades at $159 (market cap $10.08B), while Veritone Inc trades at $0.61 (market cap $59.46M). The key difference: Twist Bioscience Corp is far larger — about 169.5× Veritone Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Veritone Inc for 12 Days on average.
| TWST | VERI | |
|---|---|---|
Market Cap | $10.08B | $59.46M |
Volume | 4,229,037 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $205.00 | $8.39 |
52-Week Low | $25.45 | $0.59 |
Typical Hold Time | 27 Days | 12 Days |
Enterprise Value | $10.01B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Veritone (VERI) trades at $0.69, down 7.38% over 24 hours, reflecting ongoing investor concerns. The stock is technically bearish with negative earnings trends, including a net income margin of -117.54% for 2025. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are overshadowed by a securities class action investigation and consistent quarterly losses.
The outlook remains challenging due to persistent unprofitability and high cash burn. The consensus price target of $3.75 offers significant upside if the company can achieve cost reductions and revenue growth, but execution risks and legal overhangs present substantial headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
